Medtronic TYRX(TM) Antibacterial Envelope Reduces Cardiac Device Infection Rates at 12 Months Long-term Citadel/Centurion Clinical Trial Findings and Independent DataPresented at Heart Rhythm Society 36thAnnual Scientific Sessions DUBLIN and BOSTON – MAY 15, 2015– Medtronic plc (NYSE: MDT) today announced that its TYRX(TM) Antibacterial Envelope reduces major […]
Read more →ZELTIQ(R) Aesthetics Reaches 2,000,000th CoolSculpting(R) Treatment Cycle Milestone CoolSculpting Procedure Continues to Grow Noninvasive Fat Reduction Market PLEASANTON, CA– (Marketwired) –05/14/15–ZELTIQAesthetics, Inc.(NASDAQ: ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced it recently shipped its 2,000,000thCoolSculpting treatment […]
Read more →Expert Presented Significant Body of Data from Randomized Controlled Trials of EndoGastric Solutions Transoral Incisionless Fundoplication (TIF) Procedure for GERD at SAGES 2015 April 15, 2015 Data shows positive results from 192 patients followed up to 12-months at multiple centers SAN MATEO, Calif. EndoGastric Solutions (EGS), a […]
Read more →CoolSculpting(R) Procedure Named “Best Non-Surgical Procedure” by JEZEBEL Magazine ATLANTA, GA– (Marketwired) –04/08/15– ZELTIQAesthetics, Inc.(NASDAQ: ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology, today announced that its CoolSculpting procedure has been awarded the 2015 “Best Non-Surgical Procedure” inAtlantabyJEZEBELmagazine. The […]
Read more →Cardiac Dimensions Completes $43M Equity Financing $15.2 Million Infusion from International Investors Rounds Out Financing; Funds Will Support Landmark Trial, Expand Commercial Operations (KIRKLAND, WA), March 11, 2015Cardiac Dimensions today announced the addition of $15.2 million to its previously announced financing. Life Sciences Partners, one of Europe’s […]
Read more →ZELTIQ Announces Fourth Quarter and Full Year 2014 Financial Results Full Year 2014 Revenue of $174.5 million, Up 56% Year-Over-Year; Increases Full Year 2015 Revenue Guidance to $230 – $235 Million, ~35% Year-Over-Year; Received FDA Clearance to Perform CoolSculpting(R) at Lower Temperatures; Announced Launch of New CoolSmooth […]
Read more →EndoGastric Solutions Announces Publication of Landmark Data in Gastroenterology Demonstrating Superiority of Transoral Incisionless Fundoplication For Treatment of Troublesome Regurgitation January 21, 2015 Significantly More TIF/Placebo Patients Experienced Elimination of Troublesome Regurgitation as Compared to Sham/PPI Patients SAN MATEO, Calif.EndoGastric Solutions (EGS) announces thatGastroenterology, the official journal […]
Read more →Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System Third Multi-Center Study Shows Compelling Results Consistent with Previous Trials; Data Presented at TCT (KIRKLAND, WA), September 17, 2014Cardiac Dimensions, Inc. today announced that new long-term […]
Read more →Maker of Device to Help Improve Breathing Seeks $2.5M Posted inMedical Venture Capitalby Arundhati Parmar on February 14, 2014 Aerin Medical wants to help people with chronic nasal obstruction and other conditions improve their breathing. Aerin Medical, a Santa Clara company that makes the nonsurgical InFlux device […]
Read more →ELUSYS receives contract FOR UP TO $143 mILLION from the U.S. Federal government to fund advanced development of Anthim, a new treatment for anthrax Funding awarded by BARDA (Biomedical Advanced Research & Development Authority); Anthim being developed to treat inhaled anthrax, one of the top bioterrorism threats […]
Read more →